Hypernatremia

Hypernatremia is an electrolyte disorder characterized by an elevated serum sodium concentration, typically defined as a serum sodium level greater than 155 mEq/L in dogs and cats, although reference ranges may vary slightly by laboratory. Sodium is the primary extracellular cation and the main determinant of plasma osmolality. Hypernatremia always indicates a state of hyperosmolality, leading to cellular dehydration, particularly affecting the central nervous system. The condition can arise from either a net loss of free water (water deficit) or a net gain of sodium (hypertonic sodium load). Clinically, hypernatremia is classified based on the patient's volume status: hypovolemic (both sodium and water depleted, but water loss exceeds sodium loss), euvolemic (pure water loss), or hypervolemic (excess sodium gain). The severity of clinical signs correlates with the magnitude and rapidity of the rise in serum sodium. Acute hypernatremia (developing over hours) can cause severe neurological signs due to rapid brain cell shrinkage, while chronic hypernatremia (developing over days) allows the brain to adapt by accumulating intracellular osmolytes, reducing the risk of cerebral edema during correction. Proper diagnosis and management require a thorough understanding of water balance, renal concentrating mechanisms, and the potential for iatrogenic complications during therapy.

The etiologies of hypernatremia are diverse and can be categorized based on the underlying mechanism: water loss, sodium gain, or a combination. Pure water loss (euvolemic hypernatremia) occurs when there is inadequate water intake or excessive insensible water loss. Causes include: primary hypodipsia or adipsia (e.g., due to hypothalamic lesions, neoplasia, or trauma), lack of access to water (e.g., neglect, water deprivation), and increased insensible losses from the respiratory tract (panting) or skin (fever, burns). Diabetes insipidus (central or nephrogenic) is a classic cause of euvolemic hypernatremia due to impaired renal water conservation. Hypovolemic hypernatremia results from hypotonic fluid loss, where both sodium and water are lost, but water loss exceeds sodium loss. Causes include: gastrointestinal losses (vomiting, diarrhea, particularly osmotic diarrhea), renal losses (osmotic diuresis due to glucosuria in diabetes mellitus, mannitol administration, chronic kidney disease with impaired concentrating ability), and third-space losses (pancreatitis, peritonitis, burns). Hypervolemic hypernatremia is less common and results from excessive sodium intake or retention. Causes include: iatrogenic administration of hypertonic saline (e.g., 3% NaCl, sodium bicarbonate), accidental ingestion of table salt or salt-based products (e.g., play-dough, rock salt), hyperaldosteronism (primary or secondary), and hyperadrenocorticism (Cushing's syndrome) due to mineralocorticoid excess. In veterinary patients, the most common causes are water deprivation, diabetes insipidus, and osmotic diuresis from uncontrolled diabetes mellitus. Rarely, hypernatremia can be caused by severe burns or heat stroke due to massive water loss.

Hypernatremia is a relatively common electrolyte disturbance in small animal practice, though exact incidence rates are not well documented. It can occur in dogs and cats of any age, breed, or sex. However, certain populations are at higher risk: very young or geriatric animals, those with concurrent diseases affecting water intake (e.g., renal disease, diabetes mellitus, hyperadrenocorticism), and those with neurological conditions that impair thirst. Breed predispositions are not well established, but conditions that lead to hypernatremia, such as diabetes insipidus, may have a genetic basis in some breeds (e.g., central diabetes insipidus is more common in certain breeds like the German Shepherd). Cats may be more prone to hypernatremia due to their naturally low thirst drive and susceptibility to conditions like chronic kidney disease. In a study of hospitalized dogs, hypernatremia was present in approximately 5% of patients, with a higher prevalence in those with critical illness. The prognosis is worse in patients with severe hypernatremia (serum sodium > 170 mEq/L) and in those with underlying comorbidities. Seasonal variations may occur, with increased risk during hot weather due to heat stress and water loss.

The pathophysiology of hypernatremia revolves around the disruption of water homeostasis and the resultant hyperosmolality. Sodium is the primary determinant of extracellular fluid (ECF) osmolality, and an increase in serum sodium leads to an increase in plasma osmolality. This hyperosmolality creates an osmotic gradient that draws water out of cells, causing cellular dehydration. The brain is particularly vulnerable to this effect. In acute hypernatremia, rapid water movement out of brain cells leads to neuronal shrinkage, which can cause mechanical traction on cerebral vessels, leading to hemorrhage, subdural hematoma, and thrombosis. The brain attempts to protect itself by generating intracellular osmolytes (e.g., myo-inositol, glutamine, taurine) to restore cell volume, a process that takes 24-48 hours. This adaptation is crucial for survival but also poses a risk during treatment: if hypernatremia is corrected too rapidly, the accumulated osmolytes cause water to move into brain cells, leading to cerebral edema, which can be fatal. The underlying cause of hypernatremia also contributes to the pathophysiology. For example, in hypovolemic hypernatremia, there is a deficit in total body water and sodium, but water loss is proportionally greater. This leads to hypovolemia, which can cause hypotension, decreased tissue perfusion, and prerenal azotemia. In hypervolemic hypernatremia, there is an excess of total body sodium, leading to expansion of the ECF volume, which can cause hypertension, pulmonary edema, and peripheral edema. The clinical signs of hypernatremia are primarily neurological and include lethargy, weakness, disorientation, seizures, and coma, reflecting the severity of brain cell dehydration.

Several factors predispose animals to hypernatremia. Intrinsic factors include: age (neonates and geriatric animals have reduced renal concentrating ability and may have inadequate thirst response), underlying diseases that affect water balance (e.g., chronic kidney disease, diabetes mellitus, hyperadrenocorticism, diabetes insipidus), and neurological conditions that impair thirst perception or access to water. Extrinsic factors include: environmental conditions (e.g., hot weather, inadequate water supply), iatrogenic causes (e.g., administration of hypertonic fluids, sodium bicarbonate, or medications that cause water loss such as diuretics or corticosteroids), and dietary factors (e.g., high-sodium diets, salt poisoning). In hospitalized patients, hypernatremia can be exacerbated by inadequate fluid therapy, especially in those receiving diuretics or with ongoing losses. Additionally, certain breeds may have a genetic predisposition to conditions like central diabetes insipidus (e.g., German Shepherd, Poodle) or nephrogenic diabetes insipidus (e.g., in some dog breeds). Cats are particularly prone to hypernatremia due to their low thirst drive and high susceptibility to chronic kidney disease, which impairs urine concentrating ability.

Clinical signs of hypernatremia are primarily neurological and depend on the severity and rapidity of onset. In mild hypernatremia (serum sodium 150-160 mEq/L), signs may be subtle and include lethargy, depression, and mild weakness. As sodium levels rise (160-170 mEq/L), more pronounced signs appear: anorexia, vomiting, muscle tremors, ataxia, and behavioral changes. Severe hypernatremia (>170 mEq/L) can cause seizures, coma, and death. In acute hypernatremia, signs develop rapidly and are more severe, while in chronic hypernatremia, the brain adapts, and signs may be less pronounced for a given sodium level. Physical examination may reveal signs of dehydration (e.g., dry mucous membranes, decreased skin turgor, sunken eyes) in hypovolemic hypernatremia, or signs of volume overload (e.g., peripheral edema, pulmonary crackles, jugular distension) in hypervolemic hypernatremia. Neurological examination may show altered mentation, cranial nerve deficits, and abnormal posturing. In cases of salt poisoning, gastrointestinal signs such as vomiting and diarrhea may be prominent. Additionally, the underlying cause may present with its own clinical signs, such as polyuria and polydipsia in diabetes insipidus or diabetes mellitus, or signs of hyperadrenocorticism (e.g., alopecia, pot-bellied appearance).

The differential diagnoses for hypernatremia include conditions that cause water loss or sodium gain. Key differentials to consider are: 1) Diabetes insipidus (central or nephrogenic): characterized by polyuria and polydipsia, with dilute urine (USG < 1.010) and hypernatremia if water intake is inadequate. Diagnosis is based on water deprivation test or response to desmopressin (DDAVP). 2) Diabetes mellitus: osmotic diuresis due to glucosuria leads to water loss and hypernatremia; hyperglycemia and glucosuria are present. 3) Chronic kidney disease: impaired renal concentrating ability leads to polyuria and water loss; azotemia and isosthenuria are typical. 4) Hyperadrenocorticism (Cushing's syndrome): cortisol excess can cause polyuria and water loss; clinical signs include alopecia, pot-bellied appearance, and elevated cortisol levels. 5) Primary hyperaldosteronism (Conn's syndrome): excessive aldosterone causes sodium retention and potassium loss; hypertension and hypokalemia are common. 6) Salt poisoning (sodium chloride toxicity): history of ingestion of salt or hypertonic saline; severe hypernatremia with neurological signs. 7) Hypodipsia/adipsia: due to hypothalamic lesions or behavioral issues; inadequate water intake leads to hypernatremia. 8) Heat stroke: excessive water loss through panting and sweating; hyperthermia and dehydration are present. 9) Burns: extensive skin damage leads to water loss; history of burns. 10) Iatrogenic: administration of hypertonic fluids or sodium bicarbonate; history of treatment. To differentiate these, a thorough history, physical examination, and laboratory testing (including serum biochemistry, urinalysis, and endocrine tests) are essential.

The diagnostic approach to hypernatremia should be systematic. Step 1: Confirm hypernatremia with serum biochemistry. Step 2: Assess the patient's volume status (hypovolemic, euvolemic, hypervolemic) based on physical examination (mucous membranes, skin turgor, heart rate, blood pressure, jugular venous distension, presence of edema). Step 3: Measure urine osmolality and urine sodium concentration. In euvolemic hypernatremia, urine osmolality is typically low (< 300 mOsm/kg) in diabetes insipidus, while in hypovolemic hypernatremia, urine osmolality is high (> 600 mOsm/kg) if renal concentrating ability is intact. Step 4: Evaluate for underlying causes: check serum glucose to rule out diabetes mellitus; assess renal function (BUN, creatinine, SDMA); consider endocrine testing (ACTH stimulation test or low-dose dexamethasone suppression test for hyperadrenocorticism; aldosterone and potassium levels for hyperaldosteronism). Step 5: If diabetes insipidus is suspected, perform a water deprivation test or a trial with desmopressin (DDAVP). Step 6: In cases of suspected salt poisoning, obtain a history of exposure and measure urine sodium concentration (which will be high). Step 7: In patients with neurological signs, consider brain imaging (CT or MRI) to rule out intracranial lesions causing hypodipsia. Step 8: Throughout the diagnostic workup, monitor serum sodium frequently to guide therapy. The diagnostic algorithm should be tailored to the individual patient, but these steps provide a logical framework.

Laboratory findings in hypernatremia include: Serum biochemistry: elevated sodium (> 155 mEq/L), which may be accompanied by hyperchloremia (since chloride follows sodium). Other changes depend on the underlying cause: hyperglycemia in diabetes mellitus, azotemia (elevated BUN and creatinine) in renal disease or dehydration, and elevated cortisol in hyperadrenocorticism. In hypovolemic hypernatremia, there may be prerenal azotemia and elevated total protein and hematocrit due to hemoconcentration. In hypervolemic hypernatremia, there may be evidence of volume overload, such as low hematocrit and albumin due to dilution. Urinalysis: urine specific gravity (USG) is helpful: in diabetes insipidus, USG is low (< 1.010); in hypovolemic hypernatremia with intact renal function, USG is high (> 1.030); in chronic kidney disease, USG is isosthenuric (1.008-1.012). Urine sodium concentration can be measured: low (< 20 mEq/L) in hypovolemic states, high (> 40 mEq/L) in hypervolemic states or salt poisoning. Blood gas analysis may reveal acid-base disturbances: metabolic acidosis in diarrhea or renal failure, metabolic alkalosis in vomiting. Serum osmolality can be calculated (2 x Na + glucose/18 + BUN/2.8) and is typically elevated. Additional tests: serum potassium may be low in hyperaldosteronism, and aldosterone levels can be measured. In cases of suspected central diabetes insipidus, a water deprivation test or response to DDAVP is diagnostic. In summary, laboratory findings are essential to identify the cause and guide treatment.

Imaging studies are not typically required for the diagnosis of hypernatremia itself, but they are useful to identify underlying causes. Thoracic radiography may be indicated in patients with hypervolemic hypernatremia to assess for pulmonary edema or cardiomegaly. Abdominal ultrasonography can evaluate the kidneys (size, echogenicity, presence of calculi) in cases of chronic kidney disease, and the adrenal glands in cases of hyperadrenocorticism or hyperaldosteronism (e.g., adrenal mass). In patients with neurological signs, brain imaging (CT or MRI) is recommended to rule out intracranial lesions such as neoplasia, trauma, or inflammation that may cause hypodipsia or central diabetes insipidus. In cases of suspected salt poisoning, imaging is not helpful. Echocardiography may be indicated if cardiac disease is suspected as a cause of volume overload. Overall, imaging is used to investigate the underlying etiology rather than to diagnose hypernatremia.

Cytology and histopathology are not directly used to diagnose hypernatremia, but they may be helpful in identifying underlying causes. For example, in cases of hyperadrenocorticism, histopathology of an adrenal mass may reveal adrenocortical adenoma or carcinoma. In cases of primary hyperaldosteronism, histopathology of the adrenal gland may show an aldosterone-producing adenoma. In cases of central diabetes insipidus, histopathology of the hypothalamus or pituitary may reveal neoplasia (e.g., craniopharyngioma) or inflammation. However, these are not routine diagnostic tests for hypernatremia. In cases of salt poisoning, there are no specific cytological or histopathological findings. Therefore, cytology and histopathology are reserved for specific underlying conditions and are not part of the standard diagnostic workup for hypernatremia.

The treatment of hypernatremia depends on the underlying cause, the patient's volume status, and the rate of onset. The primary goal is to correct the hypernatremia safely, avoiding rapid shifts that can cause cerebral edema. The rate of correction should not exceed 0.5-1 mEq/L per hour, with a maximum of 10-12 mEq/L per day. In hypovolemic hypernatremia, the first priority is to restore intravascular volume with isotonic fluids (e.g., 0.9% NaCl) until the patient is hemodynamically stable. Once volume is restored, free water can be replaced using hypotonic fluids such as 0.45% NaCl or 5% dextrose in water (D5W). In euvolemic hypernatremia, free water can be replaced with D5W or 0.45% NaCl. In hypervolemic hypernatremia, the goal is to remove excess sodium, which may require diuretics (e.g., furosemide) and administration of free water. The fluid deficit can be calculated using the formula: Water deficit (L) = 0.6 x body weight (kg) x (serum Na / 140 - 1). This deficit should be replaced over 24-48 hours, with frequent monitoring of serum sodium. In cases of salt poisoning, aggressive treatment with D5W and diuretics may be necessary. Underlying causes should be addressed: for diabetes insipidus, desmopressin (DDAVP) is used; for diabetes mellitus, insulin therapy; for hyperadrenocorticism, trilostane or mitotane; for hyperaldosteronism, surgical removal of the adrenal mass or medical management with spironolactone. Supportive care includes monitoring neurological status, providing a quiet environment, and ensuring adequate nutrition. In severe cases, intensive care with continuous monitoring of serum sodium is essential.

The prognosis for hypernatremia depends on the severity, the rapidity of onset, the underlying cause, and the promptness of treatment. In mild to moderate hypernatremia (serum sodium < 170 mEq/L) that is corrected appropriately, the prognosis is generally good, especially if the underlying cause is reversible (e.g., water deprivation). However, in severe hypernatremia (> 170 mEq/L) or in cases with severe neurological signs, the prognosis is guarded to poor. Mortality rates can be high, especially in patients with concurrent diseases such as renal failure or diabetes mellitus. Chronic hypernatremia has a better prognosis than acute hypernatremia because the brain has adapted, but the risk of cerebral edema during correction is higher. Negative prognostic indicators include: serum sodium > 180 mEq/L, coma, seizures, and lack of response to therapy within 24 hours. Underlying causes that are progressive or untreatable (e.g., brain tumors) carry a poorer prognosis. With appropriate management, many patients can recover fully, but long-term monitoring is necessary to prevent recurrence.

Follow-up care for hypernatremia involves serial monitoring of serum sodium levels, especially during the correction phase. Initially, serum sodium should be checked every 2-4 hours during fluid therapy to ensure the rate of correction is appropriate. Once the patient is stable, sodium can be checked daily. The underlying cause must be managed long-term: for diabetes insipidus, desmopressin (DDAVP) is given as needed, and water intake should be monitored; for diabetes mellitus, insulin therapy and glucose monitoring are required; for hyperadrenocorticism, trilostane or mitotane therapy requires periodic monitoring of cortisol levels and clinical signs; for chronic kidney disease, regular assessment of renal function (BUN, creatinine, SDMA, urinalysis) and blood pressure is necessary. Patients with hypodipsia may require assisted water intake or a change in diet. Recheck intervals should be tailored to the underlying condition, but generally, a recheck within 1-2 weeks after discharge is recommended, followed by regular check-ups every 1-3 months. Owners should be educated on the signs of hypernatremia and the importance of ensuring adequate water intake.

Pearls: 1) Always calculate the water deficit and correct hypernatremia slowly (max 0.5-1 mEq/L/hour) to avoid cerebral edema. 2) In hypovolemic patients, restore volume with isotonic fluids first before using hypotonic fluids. 3) Use the formula: Water deficit (L) = 0.6 x body weight (kg) x (serum Na / 140 - 1) to guide fluid therapy. 4) In chronic hypernatremia, the brain has adapted, so correction should be even slower (max 0.5 mEq/L/hour) to prevent cerebral edema. 5) Always check urine specific gravity and osmolality to differentiate causes. 6) In cases of salt poisoning, consider the use of diuretics to enhance sodium excretion. Pitfalls: 1) Rapid correction of hypernatremia can cause cerebral edema, seizures, and death. 2) Using hypotonic fluids in hypovolemic patients can cause a rapid drop in sodium and worsen hypovolemia. 3) Failing to address the underlying cause leads to recurrence. 4) Overlooking the possibility of iatrogenic hypernatremia from hypertonic saline or sodium bicarbonate. 5) Not monitoring serum sodium frequently during therapy. 6) Assuming that hypernatremia is always due to water loss; consider sodium gain. 7) In patients with diabetes insipidus, water deprivation tests should be performed cautiously, as they can worsen hypernatremia.

Drug protocols for hypernatremia are primarily supportive and directed at the underlying cause. For fluid therapy: 0.9% NaCl (isotonic saline) is used for initial volume expansion in hypovolemic patients, at a rate of 10-20 mL/kg IV over 15-30 minutes, then adjusted based on hydration status. 0.45% NaCl (half-strength saline) or 5% dextrose in water (D5W) is used for free water replacement, administered at a rate calculated to correct the water deficit over 24-48 hours. The rate of sodium correction should not exceed 0.5-1 mEq/L/hour. For diabetes insipidus: Desmopressin acetate (DDAVP) is used. For central diabetes insipidus, the dose is 1-4 drops (or 0.1-0.2 mL) of the intranasal solution (0.1 mg/mL) administered into the conjunctival sac or intranasally, or 1-2 mcg subcutaneously, every 12-24 hours. For nephrogenic diabetes insipidus, DDAVP is ineffective; treatment focuses on addressing the underlying cause and ensuring water intake. For diabetes mellitus: Insulin therapy (e.g., NPH insulin, 0.25-0.5 U/kg SC q12h, or insulin glargine, 0.5 U/kg SC q12h) is used to control hyperglycemia and osmotic diuresis. For hyperadrenocorticism: Trilostane (Vetoryl) is given at 1-3 mg/kg PO q12h, with dose adjustments based on ACTH stimulation test results. Alternatively, mitotane (Lysodren) is used at 50 mg/kg/day PO for 7-10 days, then 50 mg/kg/week for maintenance. For hyperaldosteronism: Spironolactone (Aldactone) is given at 1-2 mg/kg PO q12h, and surgical removal of the adrenal mass is recommended if possible. For salt poisoning: Furosemide (Lasix) at 1-2 mg/kg IV or IM q8-12h may be used to promote sodium excretion, along with D5W administration. All drug dosages should be adjusted based on renal function and patient response. Contraindications and interactions should be considered, and monitoring is essential.

Evidence-based literature on hypernatremia in veterinary medicine is limited, but several key studies and reviews provide guidance. A retrospective study by Ueda et al. (2015) evaluated the clinical characteristics and outcomes of hypernatremia in dogs, finding that hypernatremia was associated with higher mortality, especially in patients with severe hypernatremia and concurrent diseases. Another study by Langston (2017) reviewed the management of electrolyte disorders in small animals, emphasizing the importance of slow correction to prevent neurological complications. The ACVIM consensus statement on fluid therapy (2013) provides guidelines for fluid selection and rates, including recommendations for hypernatremia. In human medicine, the principles of hypernatremia management are well-established, and these are often extrapolated to veterinary patients. A study by DiBartola (2012) in the Textbook of Veterinary Internal Medicine discusses the pathophysiology and treatment of hypernatremia in detail. Additionally, a study by Schaer (2015) highlighted the risks of rapid correction and the use of the water deficit formula. Overall, the evidence supports a cautious approach to correction, with frequent monitoring and treatment of the underlying cause. More research is needed to establish specific guidelines for veterinary patients, but current recommendations are based on physiological principles and clinical experience.